• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在非典型溶血尿毒综合征患儿的一个亚组中,特定的血管性血友病因子裂解蛋白酶(ADAMTS 13)活性严重缺乏。

Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.

作者信息

Veyradier Agnès, Obert Bernadette, Haddad Elie, Cloarec Sylvie, Nivet Hubert, Foulard Michel, Lesure François, Delattre Pierre, Lakhdari Mustapha, Meyer Dominique, Girma Jean-Pierre, Loirat Chantal

机构信息

INSERM Unité 143, Le Kremlin Bicêtre, Service de Néphrologie, Hôpital Robert Debré, Tours, France.

出版信息

J Pediatr. 2003 Mar;142(3):310-7. doi: 10.1067/mpd.2003.79.

DOI:10.1067/mpd.2003.79
PMID:12640381
Abstract

OBJECTIVE

The von Willebrand factor-cleaving protease (VWF-cp) activity has been reported to be deficient in adults with thrombotic thrombocytopenic purpura (TTP) and generally normal in adults with hemolytic uremic syndrome (HUS). The goal of this study was to determine VWF-cp activity in children with typical postdiarrheal (d+) HUS or atypical non-postdiarrheal (d-) HUS. Study design We measured VWF-cp activity in the plasma of 64 children with either (d+) HUS (n = 41) or (d-) HUS (n = 23).

RESULTS

In the acute phase of HUS, VWF-cp activity was normal (>50%) in 54 children and undetectable (<5%) in one (d+) HUS and in 6 (d-) HUS children. After a 3-month remission, the (d+) HUS patient recovered a 100% VWF-cp activity, and the 6 (d-) HUS patients kept an undetectable level. In these 6 (d-) HUS patients, the disease was characterized by a neonatal onset and several relapses (hemolytic anemia, thrombocytopenia, transient acute renal failure, cerebral ischemia), and sometimes the development of arterial hypertension or end stage renal failure.

CONCLUSION

A subgroup of pediatric patients with atypical (d-) HUS, with hematologic symptoms starting at birth and a recurrent course progressively involving kidney and brain, is related to VWF-cp deficiency and actually corresponds to Upshaw-Schulman syndrome revisited as congenital TTP.

摘要

目的

据报道,成人血栓性血小板减少性紫癜(TTP)患者的血管性血友病因子裂解蛋白酶(VWF-cp)活性缺乏,而成人溶血尿毒综合征(HUS)患者的该活性通常正常。本研究的目的是测定典型腹泻后(d+)HUS或非典型非腹泻后(d-)HUS儿童的VWF-cp活性。研究设计:我们检测了64例患有(d+)HUS(n = 41)或(d-)HUS(n = 23)儿童血浆中的VWF-cp活性。

结果

在HUS急性期,54例儿童的VWF-cp活性正常(>50%),1例(d+)HUS儿童和6例(d-)HUS儿童的VWF-cp活性检测不到(<5%)。缓解3个月后,(d+)HUS患者的VWF-cp活性恢复至100%,6例(d-)HUS患者的VWF-cp活性仍检测不到。在这6例(d-)HUS患者中,疾病表现为新生儿期起病,多次复发(溶血性贫血、血小板减少、短暂性急性肾衰竭、脑缺血),有时还会出现动脉高血压或终末期肾衰竭。

结论

一组非典型(d-)HUS的儿科患者,血液学症状始于出生,病程反复,逐渐累及肾脏和大脑,与VWF-cp缺乏有关,实际上相当于重新定义为先天性TTP的Upshaw-Schulman综合征。

相似文献

1
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.在非典型溶血尿毒综合征患儿的一个亚组中,特定的血管性血友病因子裂解蛋白酶(ADAMTS 13)活性严重缺乏。
J Pediatr. 2003 Mar;142(3):310-7. doi: 10.1067/mpd.2003.79.
2
Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).血栓性血小板减少性紫癜/溶血性尿毒症综合征(TTP/HUS)中的两种新型ADAMTS13基因突变。
Kidney Int. 2004 Sep;66(3):955-8. doi: 10.1111/j.1523-1755.2004.00841.x.
3
von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.儿童腹泻相关性溶血尿毒综合征中的血管性血友病因子裂解蛋白酶
Thromb Haemost. 2001 Jun;85(6):975-8.
4
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.血管性血友病因子裂解蛋白酶(ADAMTS13)在复发性和家族性血栓性血小板减少性紫癜及溶血性尿毒症综合征中缺乏。
Blood. 2002 Aug 1;100(3):778-85. doi: 10.1182/blood-2001-12-0166.
5
von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.儿童血栓性血小板减少性紫癜中的血管性血友病因子裂解蛋白酶及ADAMTS13突变
Blood. 2003 Mar 1;101(5):1845-50. doi: 10.1182/blood-2002-08-2399. Epub 2002 Oct 17.
6
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.血栓性血小板减少性紫癜和溶血尿毒综合征的病因及发病机制:血管性血友病因子裂解蛋白酶的作用
Best Pract Res Clin Haematol. 2001 Jun;14(2):437-54. doi: 10.1053/beha.2001.0142.
7
[Atypical hemolytic and uremic syndrome associated with von Willebrand factor-cleaving protease (ADAMTS 13) deficiency in children].
Arch Pediatr. 2013 Aug;20(8):853-7. doi: 10.1016/j.arcped.2013.05.001. Epub 2013 Jul 1.
8
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.血管性血友病因子裂解蛋白酶(ADAMTS - 13)活性测定在血栓性微血管病诊断中的应用:瑞士的经验
Semin Hematol. 2004 Jan;41(1):75-82. doi: 10.1053/j.seminhematol.2003.10.008.
9
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.血栓性血小板减少性紫癜和溶血尿毒综合征中的血管性血友病因子裂解蛋白酶
N Engl J Med. 1998 Nov 26;339(22):1578-84. doi: 10.1056/NEJM199811263392202.
10
von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Pediatr Res. 2001 May;49(5):653-9. doi: 10.1203/00006450-200105000-00008.

引用本文的文献

1
A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS.ADAMTS13 活性的适度降低与 STEC-HUS 的严重程度相关。
Biomolecules. 2023 Nov 20;13(11):1671. doi: 10.3390/biom13111671.
2
Heat-inactivated Factor B inhibits alternative pathway fluid-phase activation and convertase formation on endothelial cell-secreted ultra-large von Willebrand factor strings.热灭活因子 B 抑制内皮细胞分泌的超大 von Willebrand 因子串上替代途径液相反响的激活和转化酶形成。
Sci Rep. 2023 Apr 8;13(1):5764. doi: 10.1038/s41598-023-33007-3.
3
Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina.
血栓性微血管病:来自阿根廷一家机构的294例病例的首次报告。
EJHaem. 2021 Jan 19;2(2):149-156. doi: 10.1002/jha2.154. eCollection 2021 May.
4
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.ADAMTS13 缺乏与补体激活在血栓性微血管病发病机制中的协同作用。
Blood. 2019 Sep 26;134(13):1095-1105. doi: 10.1182/blood.2019001040. Epub 2019 Aug 13.
5
Complement factor H in AMD: Bridging genetic associations and pathobiology.AMD 中的补体因子 H:连接遗传关联和病理生物学。
Prog Retin Eye Res. 2018 Jan;62:38-57. doi: 10.1016/j.preteyeres.2017.09.001. Epub 2017 Sep 18.
6
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.因因子H点突变导致的小鼠全身性血栓形成倾向和溶血尿毒综合征
Blood. 2017 Mar 2;129(9):1184-1196. doi: 10.1182/blood-2016-07-728253. Epub 2017 Jan 5.
7
ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.ADAMTS13 内肽酶可预防血管内皮生长因子抑制剂诱导的血栓性微血管病。
J Am Soc Nephrol. 2016 Jan;27(1):120-31. doi: 10.1681/ASN.2014121165. Epub 2015 Jun 2.
8
The interaction between factor H and Von Willebrand factor.因子 H 与血管性血友病因子的相互作用。
PLoS One. 2013 Aug 26;8(8):e73715. doi: 10.1371/journal.pone.0073715. eCollection 2013.
9
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.非典型溶血尿毒综合征中的部分 ADAMTS13 缺乏。
Blood. 2013 Aug 22;122(8):1487-93. doi: 10.1182/blood-2013-03-492421. Epub 2013 Jul 11.
10
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN.DGKE 变异导致肾小球微血管病,类似于膜增生性 GN。
J Am Soc Nephrol. 2013 Feb;24(3):377-84. doi: 10.1681/ASN.2012090903. Epub 2012 Dec 28.